Suspected Ocular Toxoplasmosis in Patients with ABCA4-Related Maculopathy - Scorecard - MDSpire

Suspected Ocular Toxoplasmosis in Patients with ABCA4-Related Maculopathy

  • By

  • Maram E. A. Abdalla Elsayed

  • Vincenzo Barone

  • Robert E. MacLaren

  • January 6, 2026

  • 0 min

Share

Clinical Scorecard: Suspected Ocular Toxoplasmosis in Patients with ABCA4-Related Maculopathy

At a Glance

CategoryDetail
Condition
Key MechanismsABCA4 gene mutations affecting ATP-binding cassette transporters in photoreceptors, crucial for the visual cycle.
Target Population
Care Setting

Key Highlights

  • Macular colobomas can mimic ABCA4-associated maculopathy.
  • ABCA4-associated retinopathy has a prevalence of 1 in 8,000 to 10,000 individuals.
  • Electrophysiological and genetic testing are crucial for accurate diagnosis.
  • Genetic testing is essential for confirming ABCA4-related conditions.

Guideline-Based Recommendations

Diagnosis

  • Utilize imaging techniques such as SD-OCT and FAF, including specific patterns observed.

Management

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Clinical trials for pharmacological and gene therapies are ongoing, focusing on specific ABCA4 mutations.

        Clinical Best Practices

        • Conduct comprehensive ophthalmic examinations.
        • Utilize a multidisciplinary approach involving geneticists and ophthalmologists for optimal management.

        References

        Original Source(s)

        Suspected Ocular Toxoplasmosis in Patients with ABCA4-Related Maculopathy

        • by Maram E. A. Abdalla Elsayed, Vincenzo Barone, Robert E. MacLaren

        • January 6, 2026

        Related Content

        Atsena Reports LIGHTHOUSE data at ARVO

        Atsena Therapeutics announced positive clinical data results from Part A of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). The data were presented at the 2025 Association for Research in Vision and Ophthalmology meeting in Salt Lake City, Utah.

        • May 1, 2025

        • 3 min
        Eric Souied Joins SeaBeLife

        French biotechnology company, SeaBeLife, welcomes AMD specialist to its scientific committee

        • March 9, 2026

        • 2 min
        Biologics Tied to Lower Eye Risk in Psoriasis

        Real-world data suggest lower rates of ocular surface disease with biologics vs nonbiologic systemic therapy.